0706 GMT - GSK's first-quarter results surpassed expectations, Intron Health analysts say in a note. Its specialty-medicines business outshined disappointing sales of its respiratory syncytial virus jab Arexvy, they say. The British drugmaker posted a 1% sales beat and a 7% EBIT beat, the analysts say. While guidance remains unchanged, the worsened foreign currency outlook presents a challenge, they add. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 30, 2025 03:06 ET (07:06 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。